GLG News by Restylane Users for Wrinkles: Dermatologists

Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...

(Directly pulled from the article.) Patients were randomly assigned to receive 2 doses, 45 or 90 mg, of subcutaneous ustekinumab, given 4 weeks apart and followed by treatments every 12 weeks.  Patients randomly assigned to receive 45 mg had a sustained PASI 75 (indicating an improvement in psoriatic...

The primary efficacy endpoint was PASI75 at week 12.  Patients were between 4 and 17 years old.  It was a 48-week study. There were 106 patients initially randomized to receive Enbrel and 105 patients randomized to receive placebo. At week 12, 57% (n=60) of pediatric patients treated...

PASI75 at week 10 was 70.6% in patients receiving infliximab 3 mg/kg and 79.3% in those receiving infliximab 5 mg/kg, compared with a PASI75 (only 2.7% of patients receiving placebo reached PASI75). PASI90 was achieved in 39.1% of those receiving 3 mg/kg and 52.0% in those receiving 5 mg/kg (only...

The results demonstrated that 24.4% treated with 20 mg of oral apremilast every 12 hours reached PASI75 after 84 days (p=0.023), compared to a 10.3% reduction in the baseline score for those on placebo.  The treatment length was not mentioned in this article.

This article is important in that this is an under served market. Current scar reduction products are only modestly effective, or not effective at all. An agent which has a "70% "reported reduction in scar appearance,is safe, and only has to be used a few times has a large market and will be successful....

Acambis started pre-clinical trials with a herpes vaccine, dl5-29 HSV-2 vaccine.  Acambis holds an exclusive license under Harvard's patent rights to manufacture and sell the vaccine. There are no licensed HSV vaccines currently.

Topical retinoids, in order of weakest to strongest, include adapalene (Differin), tretinoin (either Avita or Retin-A), or tazarotene (Tazorac). Each time a new product or medication is begun, you must counsel the patient that any change in the regimen will take at least 6 weeks to show a differenc...

Renovo Group announced two Phase 2 clinical trial results for its lead drug, Juvista (human recombinant TGFβ3) in scar revision (RN1001-1009) and breast augmentation (RN1001-1010) surgery.  In the scar revision trial, where Juvista was dosed twice, it met its primary endpoint with statistical...

This new delivery system from Phosphagenics for enhancing absorption and reducing irritation will have moderate effect on the retinoid market. Retinoic Acid use has been in decline not so much because of irritation, but because of the introduction of more efficacious retinoids like Tazorac and Differin...